Literature DB >> 19925256

Alginate-antacid combinations: raft formation and gastric retention studies.

Frank C Hampson1, Ian G Jolliffe, Arash Bakhtyari, Glyn Taylor, John Sykes, Lesley M Johnstone, Peter W Dettmar.   

Abstract

BACKGROUND: Alginate-based gastroesophageal reflux disease treatments have been used extensively and fall into two main categories. Those containing alginate as the principle active agent and those containing alginate in combination with a significant amount of antacid.
METHOD: The effectiveness of the raft formed by a new alginate/antacid suspension (Gaviscon Double Action Liquid, GDAL), in which calcium carbonate was the main antacid ingredient, was compared with those of existing alginate/antacid suspensions. RESULT: GDAL had similar raft strength and improved raft resilience than Gaviscon Liquid (GL), and both were significantly greater than five other products tested. Gastric retention of GDAL was similar to that of GL.
CONCLUSION: the in vitro and in vivo performance is maintained in the new GDAL formulation even with higher antacid levels and the product is as good as, or better than, previous formulations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19925256     DOI: 10.3109/03639040903388290

Source DB:  PubMed          Journal:  Drug Dev Ind Pharm        ISSN: 0363-9045            Impact factor:   3.225


  8 in total

1.  An alginate-antacid formulation (Gaviscon Double Action Liquid) can eliminate or displace the postprandial 'acid pocket' in symptomatic GERD patients.

Authors:  M A Kwiatek; S Roman; A Fareeduddin; J E Pandolfino; P J Kahrilas
Journal:  Aliment Pharmacol Ther       Date:  2011-05-03       Impact factor: 8.171

2.  pH responsive alginate polymeric rafts for controlled drug release by using box behnken response surface design.

Authors:  Ghulam Abbas; Muhammad Hanif; Mahtab Ahmad Khan
Journal:  Des Monomers Polym       Date:  2016-09-11       Impact factor: 2.650

3.  Randomised clinical trial: the effectiveness of Gaviscon Advance vs non-alginate antacid in suppression of acid pocket and post-prandial reflux in obese individuals after late-night supper.

Authors:  Mohd Adli Deraman; Muhammad Ilham Abdul Hafidz; Rona Marie Lawenko; Zheng Feei Ma; Mung Seong Wong; Cathal Coyle; Yeong Yeh Lee
Journal:  Aliment Pharmacol Ther       Date:  2020-04-28       Impact factor: 8.171

Review 4.  Review of recent evidence on the management of heartburn in pregnant and breastfeeding women.

Authors:  Raja Affendi Raja Ali; Jamiyah Hassan; Laurence J Egan
Journal:  BMC Gastroenterol       Date:  2022-05-04       Impact factor: 2.847

5.  Formulation and optimisation of raft-forming chewable tablets containing H2 antagonist.

Authors:  Shailesh T Prajapati; Anant P Mehta; Ishan P Modhia; Chhagan N Patel
Journal:  Int J Pharm Investig       Date:  2012-10

6.  Evaluation of an Innovative Over-the-Counter Treatment for Symptoms of Reflux Disease: Quick-Dissolving Alginate Granules.

Authors:  Vicki Strugala; Peter W Dettmar; Edward C M Thomas
Journal:  ISRN Pharm       Date:  2012-12-23

7.  Randomised clinical trial: the clinical efficacy and safety of an alginate-antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (GERD) in China.

Authors:  J Sun; C Yang; H Zhao; P Zheng; J Wilkinson; B Ng; Y Yuan
Journal:  Aliment Pharmacol Ther       Date:  2015-07-31       Impact factor: 8.171

8.  Sustained proton pump inhibitor deprescribing among dyspeptic patients in general practice: a return to self-management through a programme of education and alginate rescue therapy. A prospective interventional study.

Authors:  Cathal Coyle; Russell Symonds; Jane Allan; Sarah Dawson; Sheldon Russell; Adam Smith; Colin Daff; Helen Kotze
Journal:  BJGP Open       Date:  2019-10-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.